⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485088 | 0.79 | — | — | |
| SCHEMBL21743080 | 0.79 | ESR2 (0.36) | — | |
| SCHEMBL580930 | 0.74 | APLNR (0.32) | — | |
| SCHEMBL15922806 | 0.74 | — | — | |
| SCHEMBL19011948 | 0.74 | KDM4E (0.43) | — | |
| SCHEMBL8095966 | 0.72 | MAPT (0.32) | — | |
| SCHEMBL15040100 | 0.72 | NCF1 (0.44) | — | |
| SCHEMBL19011969 | 0.72 | — | — | |
| SCHEMBL2703732 | 0.72 | APLNR (0.36) | — | |
| SCHEMBL22824167 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230331768-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331768-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3529256-B1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| EP-4105223-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-107001936-B | Liquid crystal compound and liquid crystal composition containing same | 株式会社东进世美肯 | 2020-12-18 | — | — | CN | disclosed |
| EP-3619200-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| CN-110770214-A | Heterocyclic P2X7 antagonists | 阿克萨姆股份公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20170298072-A1 | Triazolopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-10-19 | — | — | US | disclosed |
| EP-3204387-A1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2017-08-16 | — | — | EP | disclosed |
| CN-107001936-A | Liquid crystal compound and liquid crystal composition containing same | 株式会社东进世美肯 | 2017-08-01 | — | — | CN | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2016055618-A1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-04-14 | — | — | WO | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2951180-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120748-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |